Background: The Centers for Medicare and Medicaid Services (CMS) considers that contralateral carotid artery occlusion puts the patients at high risk for carotid endarterectomy (CEA) and agrees to reimburse for carotid artery stenting (CAS) in these patients. However, there is a paucity of evidence that support the superiority of CAS compared with CEA in patients with contralateral carotid occlusion.
Carotid artery revascularization procedures are crucial interventions for primary and secondary stroke prevention along with optimal medical management. 1 Carotid artery stenting (CAS) had been increasingly adopted as a minimally invasive alternative to carotid endarterectomy (CEA), the gold standard open surgical approach. Several randomized clinical trials attempted to evaluate the effectiveness and safety of both procedures. [2] [3] [4] [5] [6] Clinical equipoise between those procedures was recommended in most of those randomized controlled trials, albeit careful interpretation of the results, inclusion criteria, and definition of the primary end point are warranted.
The most common cause of carotid artery disease is atherosclerosis. Therefore, it is not uncommon to observe involvement of both carotid arteries with variable degrees of stenosis and lesion severity. Prior studies have shown that patients with contralateral carotid occlusion (CCO) have worse outcomes after CEA. [7] [8] [9] This can be partly caused by diminished cerebral perfusion resulting from the lack of collateral circulation and the generally more advanced atherosclerotic disease. Yet several studies challenged these findings by showing similar outcomes between patients with a patent vs occluded contralateral carotid artery. [10] [11] [12] To add to the conflicting evidence, the procedure of choice to revascularize the carotid artery in this group of patients is still an area of debate. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial recognized CCO as a high-risk criteria for CEA and proposed better outcomes after CAS. 6 A review of literature elucidated similar outcomes after CEA between patients with and without CCO and suggested that CCO should not be considered an anatomic risk factor for CEA, which contradicts the SAPPHIRE recommendation. 13 In addition, the Centers for Medicare and Medicaid Services (CMS) covers the cost of CAS under embolic protection for their beneficiaries if they are considered high risk for CEA with symptomatic carotid artery stenosis $70% or asymptomatic patients with stenosis >80% under CMS approved clinical trials.
14 CCO is considered as an anatomic high risk for CEA, and Medicare subsequently reimburses CAS for patients with this condition and appropriate symptomatic status and degree of stenosis. However, the broad spectrum of what qualifies as high-risk criterion for CEA according to CMS enticed wide criticism from experts. 15 This study compared the postoperative outcomes after CAS and CEA in an exclusive cohort of patients with CCO and identified the factors that contributed to those outcomes in this particular population. This would potentially assist maximizing patient's care and refining current reimbursement policies for these procedures.
METHODS
Study design and database. This retrospective study compared the postoperative outcomes of carotid revascularization between CEA and CAS in patients with CCO captured in the Vascular Quality Initiative (VQI) between January, 1, 2005, and July, 31, 2016 . 16 The VQI is a multicenter registry that provides detailed information extracted from patients' medical records regarding patients' demographic characteristics, comorbidities, operative variables, and postoperative events across the United States and the Province of Ontario, Canada. For the years under study, a contralateral carotid procedure for patients with carotid artery occlusion took place in 259 centers by 1064 surgeons. The VQI Research Advisory Committee approved this study protocol. The Johns Hopkins Institutional Review Board waived individual patient consent because the study was a secondary analysis of deidentified registry.
Study population. Patients with 100% CCO were identified via the variable coded as the contralateral degree of stenosis. Degree of stenosis was obtained from the most severe stenosis recorded for the patient by duplex ultrasound imaging, magnetic resonance angiography, computed tomography angiography, or arteriogram. Symptomatic status was defined as the occurrence of ipsilateral amaurosis fugax, transient ischemic attack, or minor or major stroke before the procedure. Race was dichotomized into white vs nonwhite. Diabetes mellitus was defined as any record of diabetes whether controlled by diet, oral antihyperglycemic agents, or insulin. Chronic obstructive pulmonary disease (COPD) was defined as patients with COPD receiving treatment or supported with home oxygen. Medications before surgery were assessed as any previous intake regardless of therapeutic duration and generic type. The estimated glomerular filtration rate was calculated using the Modi Outcomes. The comparative effectiveness of CEA vs CAS in patients with CCO was assessed by evaluating short-and long-term outcomes. Thirty-day stroke was defined as any minor or major stroke irrespective to laterality. Thirty-day major adverse cardiac events (MACE) was defined as the occurrence of any stroke, myocardial infarction (MI), or death #30 days from the procedure. Long-term outcomes were defined as 2-year ipsilateral stroke and 2-year any stroke or death.
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Statistical analysis. Descriptive summary analysis was performed to compare the baseline characteristics between patients undergoing CEA and CAS. The mean 6 standard deviation was used to report continuous variables, and the Pearson c 2 and Fisher exact tests were used to summarize the categoric variables. The risk of short-term (30-day) outcomes was assessed by bivariate and multivariable robust logistic regression analyses clustering the observations in each center to reduce the bias from hospital-level unmeasurable factors. By clustering the events within centers, intergroup correlation is accounted for. Follow-up of at least 30 days was documented in 97.8% of the cohort.
The risk factors used in the multivariable models were selected based on clinical judgement and the results of bivariate analysis. Models were checked by the HosmerLemeshow goodness-of-fit in fear of overfitting while adjusting for all possible risk factors. Receiver operating characteristic curves were created to evaluate the overall predictive ability of the models. Two-year outcomes were explored via survival analysis. Log-rank tests, Kaplan-Meier estimates, and proportional hazard Cox regression analyses were used for this purpose. The Cox regression models were also clustered by centers. The available follow-up was used to censor patients at 2 years. No observation was excluded based on follow-up.
To take into consideration the temporal variation in which centers joined the VQI and the learning curve of the two procedures, particularly in patients with CCO, we created a time-varying covariate by dividing the years of surgery into three equal quintiles based on number of observations (2005-2013, 2014, 2015-2016) . Proportional hazard assumption was considered met if this variable was not significantly interacting with the logarithmic function of the analysis time. Analysis was stratified by symptomatic status. Subgroup analysis excluding patients who developed events during the periprocedural period was also implemented. All analyses were performed using Stata 14.0 software (StataCorp LP, College Station, Tex). The significance level was determined as a two-sided P value of <.05.
RESULTS
Patient cohort. During the study period, 4326 patients were identified as having complete CCO who underwent a carotid revascularization procedure. Of those patients, 3274 (75.7%) underwent CEA, and 1052 (24.3%) had CAS. The two procedures groups were similar in age, gender, insurance status, living condition, and ambulatory status. Patients who underwent CAS were more likely to be of nonwhite race compared with the CEA group (9.5% vs 7.6%; P ¼ .048). In addition, patients who had CAS showed higher prevalence of congestive heart failure (15.6% vs 9.6%; P < .001) and COPD (20 Ipsilateral symptomatic presentation was more reported in patients undergoing CAS (41.2% vs 24.2%; P < .001). Whereas the proportion of patients with $70% ipsilateral stenosis was higher in the CEA group (91.3% vs 88.2%; P ¼ .003). CAS in patients with CCO was performed by surgeons with a fewer number of cases over the entire study period (1-3 cases/surgeon), whereas CEA was more often performed by surgeons who routinely did the repair for patients with CCO (>12 cases/surgeon; Table I ). A shunt was used in 73.9% of CEA operations, and patching was reported in 91.7%. The CEA was mostly conventional (90.6%), and only 28.1% had electroencephalograph monitoring during the procedure. Femoral access was used in 94.3% of CAS patients, and the transcarotid approach was used in 4.8%. The mean stent length used was 36 6 8.9 mm. Additional operative factors are reported in Table I .
Absolute proportions of outcomes. The proportion of patients who developed stroke #30 days from the procedures did not differ between the two procedures in asymptomatic patients (2.2% in CEA vs 1.8% in CAS; P ¼ .495). However, CAS carried a higher probability of 30-day stroke in symptomatic patients (3.5% vs 1.7%; P ¼ .042). Similarly, compared with the CEA group, symptomatic patients in the CAS group had higher rates of 30-day death (4.4% vs 1.0%; P < .001), 30-day stroke/ death (6.5% vs 2.3%, P < .001), and 30-day MACE (6.7% vs 3.9%; P ¼ .032), but those outcomes were similar in asymptomatic patients. The percentage of postoperative MI after both procedures in symptomatic patients was higher in the CEA group (1.8% vs 0.2%; P ¼ .026). Asymptomatic patients exhibited significantly higher proportions for 2-year any stroke or death after CAS than after CEA (9.9% vs 7.4%; P ¼ .019), and this result did not change after 30-day events were excluded (7.6% vs 5.4%; P ¼ .008) (Table II) . Table III) .
The multivariable regression analyses of the five perioperative outcomes with all confounders controlled for in the models are depicted in Figs 1, 2, and 3. All models showed good fit by the Hosmer-Lemeshow test (all P > .05). The areas under the curve ranged from 62.5% for 30-day MACE in asymptomatic patients to 82.0% for postoperative MI in symptomatic patients ( Supplementary Fig, online only) . (Table IV) . In contrast, the hazard of 2-year any stroke or death was exacerbated with CAS regardless of asymptomatic (aHR, 1.42; 95% CI, 1.08-1.86; P ¼ .011) or symptomatic (aHR, 1.94; 95% CI, 1.18-3.19; P ¼ .009) status. The Kaplan-Meier estimates showed better survival for patients undergoing CEA (Fig 4) .
Diabetes was associated with higher risk for stroke/ death in asymptomatic patients (aHR, 1.30; 95% CI, 1.06-1.58; P ¼ .011) but did not show an influential effect in symptomatic patients. Similarly, congestive heart failure conferred higher risk for stroke/death in asymptomatic patients only (aHR, 1.42; 95% CI, 1.08-1.88; P ¼ .012). COPD was associated with higher risk for stroke/death in both groups (both P < .05). Preoperative statin was associated with a remarkable 32% stroke or death risk reduction in symptomatic patients (aHR, 0.68; 95% CI, 0.50-0.93; P ¼ .017) ( Table V) .
The annualized incidence rates for 2-year stroke was higher for symptomatic than for asymptomatic patients after both procedures, yet were comparable in asymptomatic patients undergoing CEA or CAS (incidence rate ratio [IRR], 1.06; 95% CI, 0.48-2.14; P ¼ .841). Although 
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Two-year outcomes excluding periprocedural events. Interestingly, 83 ipsilateral strokes occurred during the 2 years of follow-up, yet most of them (54 [65.1%]) happened #30 days from the procedure. Excluding 30-day ipsilateral stroke, the type of procedure did not determine the 2-year stroke risk. Likewise, analysis of 2-year stroke/death excluding periprocedural events rendered the risk difference between the two procedures not statistically significant (Table III) .
DISCUSSION
Patients with complete carotid artery occlusion undergoing contralateral carotid revascularization demonstrated equivalent outcomes between CEA and CAS if they were asymptomatic. However, the odds of 30-day stroke, death, and MACE were threefold to sixfold higher after CAS in symptomatic patients. The lower periprocedural adverse outcomes dictated a long-term risk reduction of stroke or death after CEA. The presence of CCO is often instinctively perceived as an alarming sign of diffuse vascular disease, yet studies evaluating the natural history of the condition had suggested that CCO was nonthreatening, perhaps because an occluded vessel could not be a source of an active thromboembolic event and, therefore, would not carry excess risk of stroke or death. 18, 19 Furthermore, the available evidence of added risks of CCO after CEA or CAS is contradictory. A meta-analysis by Antoniou et al 20 concluded that CCO was implicated in worse outcomes after CEA compared with patients with no CCO, but other studies minimized the effect of CCO on the post-CEA course. Yet most those studies were from single academic institutions with excellent surgical expertise but were limited by the small sample size and the publication bias that halts investigators from reporting negative results. [10] [11] [12] 21, 22 Despite the ample of literature evaluating the safety of CEA in patients with CCO, there is a paucity of evidence discussing the outcomes after CAS. A series of 23 patients with CCO who underwent CAS revealed no incidence of 30-day stroke or death. 23 The patients in this study who underwent CAS with CCO had a higher prevalence of comorbid conditions, such as congestive heart failure and COPD, and were more likely to be of nonwhite race, all known to be associated with worse perioperative outcomes. 26, 27 Symptomatic patients were more likely to undergo CAS, reflecting potential differential referral for the revascularization procedure based on symptomatic status. 28 Not surprisingly, patients who were treated for a restenotic lesion were more likely to get CAS. This reflects the fact that CAS carries favorable outcome compared with redo-CEA. 29 Of note, patients with prior failed CEA on the side of the occlusion were more likely to have CAS (12.6% vs 6.9%; P < .001).
In this multicenter cohort, surgeons who frequently operate on patients with CCO were more likely to choose CEA (Table I) . Because most of the physicians in the VQI database are vascular surgeons, the choice of the procedure was likely not biased by the surgeons' own preference of the procedure. This might be observed in other specialties where the training is limited to a certain approach. A shunt was used in nearly 74% of CEA procedures. Routine shunting in patients with CCO was found beneficial in reducing CEA complications by minimizing clamp time in an already compromised cerebral circulation. 30 In contrast, Bydon et al 31 minimized the role of shunting for those patients provided that the posterior cerebral circulation was sufficient. It is also the senior author's (M.M.) experience not to need a shunt in patients with CCO. The risk-to-benefit assessment of technical factors, although crucial, was out of the scope of this study, which aimed at comparing the safety and effectiveness of CAS and CEA in the presence of CCO.
The presented results agree with the findings from previous comparative studies investigating the performance of CEA and CAS. Brewster et al, 32 . 33 Yet the first study did not account for the role of symptomatic status, and ICSS randomized only symptomatic patients. Symptomatic status in our analysis demonstrated an effect modification role: CEA was far more superior in symptomatic patients, whereas CAS did not offer a protective effect against adverse outcomes compared with CEA in asymptomatic patients. Moreover, those studies were limited by the small sample size and might have been underpowered to detect a significant difference. In addition, the overall perioperative CEA risk of stroke and death was 2.1% and 1.1%, respectively. These percentages are on the lower range of previously reported rates of 1.9% to 6.7%. [34] [35] [36] [37] [38] The rates of adverse events after CAS were uniformly higher than after CEA, and the risk is more pronounced in symptomatic patients, which Touzé et al 39 had previously validated in their Kaplan-Meier estimates of the 2-year freedom of stroke or death stratified by symptomatic status. Carotid endarterectomy (CEA; blue) was superior to carotid artery stenting (CAS; red) in both asymptomatic and symptomatic patients, but the benefit is more pronounced in symptomatic group. The standard error did not exceed 10% throughout the follow-up period for any study group. CI, Confidence interval.
systematic review of perioperative CAS outcomes. The annualized incidence rates in this cohort were relatively high but comparable to what had been observed before. Within each study group, the rate of 2-year any stroke/death was remarkably higher than the rate of ipsilateral stroke, which indicates that contralateral strokes and overall patients' comorbidities are largely implicated in the long-term adverse outcomes. This had been described previously by AbuRahma et al, 40 where the rate of contralateral neurologic events after CEA in patients with CCO was 14.3%. This finding might be explained by concomitant intracranial arterial disease or by watershed infarcts in cortical areas that are already hypoperfused. Finally, the Medicare criteria for CAS reimbursement had been heavily criticized, and the validity of those factors to prefer CAS had been questioned. 15, 41 The list of CMS high-risk criteria had several medical and anatomic factors that do not contribute equally to the risk of CEA. Giles et al 42 showed that stroke rates were greater in CAS patients regardless of their risk criteria. However, the authors were limited by the lack of anatomic details in a large administrative database. Schermerhorn et al 43 showed that contralateral occlusion increases the odds of stroke after CEA and death after CAS, but the authors did not directly compare the procedures, so no conclusion could be withdrawn about the clinical superiority of any of them. In our study, which to our knowledge, is the largest population-based investigation of patients with CCO, we showed that the presence of CCO does not justify CAS, which is in line with several former but smaller studies. 32, 33 This study has several limitation related to its retrospective design. First, selection bias by indication is unavoidable when comparing two procedures without randomization. However, we attempted to adjust for all possible measurable confounders that might influence the postoperative course and varied between the comparison groups (Table I) . Besides, there is a persistent need to perform observation studies to evaluate the real-world outcomes and describe the current practice in order to provide insights to possible areas of quality improvement, particularly by using multicenter heterogeneous population-based data sets. 44 Second, the VQI registry is prone to data entry imprecision and under-reporting. However, the Society for Vascular Surgery continuously performs audits to ensure complete entry of consecutive cases using hospital and physician billing data. 16 Third, follow-up information is suboptimal for the VQI and it was differentially less for patients undergoing stenting; therefore, our analysis was restricted to 2 years. Nevertheless, we believe that the consequences related to carotid revascularization tend to occur early in the postoperative course. In addition, the hazard was proportional over time when the long-term failures were evaluated, a key assumption for the validity of survival analysis.
Lastly, VQI does not deliver information about collateral cerebral circulation status, for example, the flow in the vertebral or the external carotid arteries is not captured, which might significantly mitigate the effect of the diseased opposite carotid artery and minimize the risk of cerebrovascular accidents.
CONCLUSIONS
In this exclusive large cohort of patients undergoing carotid artery revascularization in the presence of CCO, we concluded that the performance of CAS and CEA varied based on the patient's symptomatic status. Although CEA and CAS had equivalent performance in asymptomatic patients, CEA was far more superior in symptomatic patients. CAS posed a significantly larger risk for 30-day stroke, death, and MACE despite our adjusting for all possible risk factors in symptomatic patients. The postoperative difference contributed to the 2-year favorable results after CEA in symptomatic patients with CCO.
These findings challenge the widespread yet previously criticized misconception that CCO places the patient at high risk for CEA. Careful patient selection for the appropriate procedure and refinement of current guidelines are prudent to provide the best evidence-based health care and proper use of Medicare resources. Review of existing reimbursement policies and expansion of current randomized controlled trials to include patients with contralateral occlusion are warranted in the highlight of the evidence presented in this study.
The role of shunting in patients with contralateral occlusion is certainly an important area of study. However, we sought to compare both procedures' performance in patients with contralateral occlusion in the context of current real-world practice in which some surgeons prefer to shunt and others prefer not to. Therefore, we believe that identifying the risk/benefit of factors contributing to favorable outcomes following each procedure was out of the scope of this study. We certainly agree, however, that future research is warranted to optimize the perioperative course for each procedure in patients with contralateral carotid occlusion.
Regarding the third and the fourth questions, we would like to thank you, Dr AbuRahma, for bringing to the discussion the role of symptomatic status. Symptomatic lesions had consistently shown higher adverse event rates. This is likely the result of plaque instability. While carotid endarterectomy removes the plaque altogether, carotid artery stenting stabilize the existing plaques. Manipulating the lesion by insertions of wires and stents could explain the higher stroke rate with CAS compared to CEA. The effect of symptomatic status had been described in the CREST trial where the risk of stroke following CAS is more pronounced in symptomatic patients. On the other hand, a patient who has the predilection to form an unstable symptomatic lesion might have similar diffuse atherosclerotic lesions in other vital vessels that might increase his/her overall mortality risk. We believe that symptomatic presentation is just a distant surrogate to unstable, more malicious lesions.
